Medtech company HeraMED (ASX: HMD) has seen a major spike in investor confidence after securing clearance from the US Food and Drug Administration (FDA) for HeraBEAT US – their fetal ultrasonic heart monitor.
Intended to detect, display and replay heart beats from as early as 12 weeks into pregnancy, the handheld device was developed in collaboration with the Mayo Clinic, various medical institutions and hospitals.
“Receiving FDA 510(k) clearance for the HeraBEAT US device is a tremendous achievement for HeraMED,” said HeraMED CEO and Co Founder, David Groberman.
“The device development and testing, providing substantial evidence of the safety and effectiveness of the device, has passed a challenging and rigorous period of review by FDA and is now ready for distribution throughout the United States in the coming months.”
Having lodged an application for HeraBEAT with the FDA in April 2019, approval will now enable commercialisation of the device in a market where there are approximately 4 million pregnancies annually in the United States.
Following the confirmation of FDA approval, shares in HeraMED reached a high of $0.325 per share in morning trade, a rise of 51% on the day’s previous close price of $0.215.
FDA approval of HeraBEAT US continues a flow of regulatory approvals achieved by HeraMED which is using technology and innovative uses of pregnancy data to re-shape traditional relationships between doctors and pregnant women by providing greater means for engagement during pregnancy.
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
- Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
- Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
- ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
Leave a Comment
You must be logged in to post a comment.